-
公开(公告)号：US11952375B2
公开(公告)日：2024-04-09
申请号：US17484564
申请日：2021-09-24
Applicant: eFFECTOR Therapeutics Inc.
Inventor： Siegfried H. Reich , Paul A. Sprengeler , Stephen E. Webber , Alan X. Xiang , Justin T. Ernst , Bennett C. Borer , Samuel Sperry , Jo Ann Z. Wilson
IPC: C07D471/04 , A61K31/506 , A61P35/00
CPC classification number: C07D471/04 , C07B2200/13
Abstract: The present invention provides crystalline solids of 6′-((6-aminopyrimidin-4-yl)amino)-8′-methyl-2′H-spiro[cyclohexane-1,3′-imidazo[1,5-a]pyridine]-1′,5′-dione:
The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.-
公开(公告)号：US20170266185A1
公开(公告)日：2017-09-21
申请号：US15611966
申请日：2017-06-02
Applicant: eFFECTOR Therapeutics, Inc.
Inventor： Siegfried H. Reich , Paul A. Sprengeler , Stephen E. Webber , Alan X. Xiang , Justin T. ERNST
IPC: A61K31/506 , A61K31/52 , A61K31/519 , C07D487/04 , C07D473/34 , C07D519/00 , C07D495/20 , C07D491/20 , C07D471/20 , C07D471/10 , C07D471/04 , A61K31/551
CPC classification number: A61K31/506 , A61K31/519 , A61K31/52 , A61K31/551 , C07D471/04 , C07D471/10 , C07D471/20 , C07D473/34 , C07D487/04 , C07D491/20 , C07D495/20 , C07D519/00
Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4a, R4b, R5, R6, R7, R8, W1, W2, Y and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula I compounds as well as methods for utilizing the compounds of Formula I and the pharmaceutically acceptable compositions of Formula I compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.
-
3.发明申请公开(公告)号：US20170121346A1
公开(公告)日：2017-05-04
申请号：US15337184
申请日：2016-10-28
Applicant: eFFECTOR THERAPEUTICS, INC.
Inventor： Paul A. Sprengeler , Siegfried H. Reich , Justin T. Ernst , Stephen E. Webber , Mike Shaghafi , Douglas Murphy , Chinh Tran
IPC: C07D498/04 , C07D403/12 , C07D239/42 , C07D403/14 , C07D409/12 , C07D239/48 , C07D409/14 , C07D487/04 , C07D471/04 , C07D471/10 , C07D491/107 , C07D401/12 , C07D473/34 , C07D417/12
CPC classification number: C07D498/04 , C07D239/42 , C07D239/48 , C07D239/49 , C07D401/12 , C07D403/12 , C07D403/14 , C07D409/12 , C07D409/14 , C07D417/12 , C07D471/04 , C07D471/10 , C07D473/34 , C07D487/04 , C07D491/107
Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A1, A2, A3, A4, A5, W1, Y, R1, R2, R3, R4, R5, R6a, R6b, R7, R8, R8a, R8b, R9, R9a, R9b, and R10 and subscript “n” are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
-
公开(公告)号：US20190209560A1
公开(公告)日：2019-07-11
申请号：US16178678
申请日：2018-11-02
Applicant: eFFECTOR Therapeutics, Inc.
Inventor： Siegfried H. Reich , Paul A. Sprengeler , Stephen E. Webber , Alan X. Xiang , Justin T. Ernst
IPC: A61K31/506 , A61K31/551 , A61K31/52 , A61K31/519 , C07D519/00 , C07D495/20 , C07D471/04 , C07D471/20 , C07D471/10 , C07D487/04 , C07D473/34 , C07D491/20
CPC classification number: A61K31/506 , A61K31/519 , A61K31/52 , A61K31/551 , C07D471/04 , C07D471/10 , C07D471/20 , C07D473/34 , C07D487/04 , C07D491/20 , C07D495/20 , C07D519/00
Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4a, R4b, R5, R6, R7, R8, W1, W2, Y and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula I compounds as well as methods for utilizing the compounds of Formula I and the pharmaceutically acceptable compositions of Formula I compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.
-
5.发明申请公开(公告)号：US20190152988A1
公开(公告)日：2019-05-23
申请号：US16171606
申请日：2018-10-26
Applicant: eFFECTOR THERAPEUTICS, INC.
Inventor： Paul A. Sprengeler , Siegfried H. Reich , Justin T. Ernst , Stephen E. Webber , Mike Shaghafi , Douglas Murphy , Chinh Tran
IPC: C07D498/04 , C07D487/04 , C07D417/12 , C07D409/12 , C07D239/49 , C07D239/42 , C07D403/14 , C07D491/107 , C07D403/12 , C07D239/48 , C07D409/14 , C07D471/04 , C07D471/10 , C07D473/34 , C07D401/12
Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A1, A2, A3, A4, A5, W1, Y, R1, R2, R3, R4, R5, R6a, R6b, R7, R8, R8a, R8b, R9, R9a, R9b, and R10 and subscript “n” are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
-
Patent Agency Ranking
公开(公告)号：US20180085368A1
公开(公告)日：2018-03-29
申请号：US15809011
申请日：2017-11-10
Applicant: eFFECTOR Therapeutics, Inc.
Inventor： Siegfried H. Reich , Paul A. Sprengeler , Stephen E. Webber , Alan X. Xiang , Justin T. Ernst
IPC: A61K31/506 , A61K31/551 , C07D473/34 , C07D487/04 , C07D471/10 , C07D471/20 , C07D471/04 , C07D495/20 , C07D519/00 , A61K31/519 , A61K31/52 , C07D491/20
CPC classification number: A61K31/506 , A61K31/519 , A61K31/52 , A61K31/551 , C07D471/04 , C07D471/10 , C07D471/20 , C07D473/34 , C07D487/04 , C07D491/20 , C07D495/20 , C07D519/00
Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4a, R4b, R5, R6, R7, R8, W1, W2, Y and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula I compounds as well as methods for utilizing the compounds of Formula I and the pharmaceutically acceptable compositions of Formula I compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.
-
7.发明申请公开(公告)号：US20170121339A1
公开(公告)日：2017-05-04
申请号：US15337237
申请日：2016-10-28
Applicant: EFFECTOR THERAPEUTICS, INC.
Inventor： Paul A. Sprengeler , Siegfried H. Reich , Justin T. Ernst , Stephen E. Webber
IPC: C07D487/04 , C07D519/00
CPC classification number: C07D487/04 , C07D471/04 , C07D519/00
Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A1, A2, A3, A4, A5, A6, A7, W1, R1, R2, R3, R4, R5a, R5b, R6, R7, R7a, R7b, R8, R8a, R8b, R9, R9a, R9b and R10 and subscripts “m” and “n” are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
-
公开(公告)号：US20210338673A1
公开(公告)日：2021-11-04
申请号：US17308486
申请日：2021-05-05
Applicant: eFFECTOR Therapeutics Inc.
Inventor： Siegfried H. Reich , Paul A. Sprengeler , Stephen E. Webber , Alan X. XIANG , Justin T. Ernst
IPC: A61K31/506 , C07D473/34 , C07D487/04 , C07D471/04 , C07D471/10 , C07D471/20 , C07D491/20 , C07D495/20 , C07D519/00 , A61K31/519 , A61K31/52 , A61K31/551
Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4a, R4b, R5, R6, R7, R8, W1, W2, Y and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula I compounds as well as methods for utilizing the compounds of Formula I and the pharmaceutically acceptable compositions of Formula I compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.
-
公开(公告)号：US20160317536A1
公开(公告)日：2016-11-03
申请号：US15187854
申请日：2016-06-21
Applicant: eFFECTOR Therapeutics, Inc.
Inventor： Siegfried H. Reich , Paul A. Sprengeler , Stephen E. Webber , Alan X. Xiang , Justin T. ERNST
IPC: A61K31/506 , A61K31/52 , A61K31/551 , A61K31/519
CPC classification number: A61K31/506 , A61K31/519 , A61K31/52 , A61K31/551 , C07D471/04 , C07D471/10 , C07D471/20 , C07D473/34 , C07D487/04 , C07D491/20 , C07D495/20 , C07D519/00
Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4a, R4b, R5, R6, R7, R8, W1, W2, Y and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula I compounds as well as methods for utilizing the compounds of Formula I and the pharmaceutically acceptable compositions of Formula I compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.
Abstract translation: 或其立体异构体，互变异构体或其药学上可接受的盐，其中R1，R2，R3，R4a，R4b，R5，R6，R7，R8，W1，W2，Y和n如本文所定义。 还描述了式I化合物的药学上可接受的组合物以及利用式I化合物和式I化合物的药学上可接受的组合物作为Mnk抑制剂以及用于治疗诸如癌症的疾病的治疗剂的方法。
-
公开(公告)号：US20220119387A1
公开(公告)日：2022-04-21
申请号：US17484564
申请日：2021-09-24
Applicant: eFFECTOR Therapeutics Inc.
Inventor： Siegfried H. REICH , Paul A. Sprengeler , Stephen E. Webber , Alan X. Xiang , Justin T. Ernst , Bennett C. Borer , Samuel Sperry , Jo Ann Z. Wilson
IPC: C07D471/04
Abstract: The present invention provides crystalline solids of 6′-((6-aminopyrimidin-4-yl)amino)-8′-methyl-2′H-spiro[cyclohexane-1,3′-imidazo[1,5-a]pyridine]-1′,5′-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.026 seconds)
